Clinical trials: Influenza Virus Infection
Seasonal Influenza
Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2009/2010
This study is an annual trial for registration of inactivated split influenza vaccine with strain composition for season 2009/2010.
- Trial name
- NCT00945841
- Testing
- inactivated split influenza vaccine
- Where
- 3 sites in Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Safety, and Immunogenicity of Two Influenza Vaccines in Healthy Subjects 3 to 64 Years Old
This protocol is designed to evaluate safety, clinical tolerability and immunogenicity of the 2007 southern hemisphere formulation of a Novartis conventional influenza vaccine licensed in the EU and many other worldwide…
- Trial name
- NCT00464672
- Testing
- Influenza virus vaccine, Comparator influenza vaccine
- Where
- 2 sites in Argentina
- Volunteers
- 1,893 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Single Dose Escalating Study of DAS181 in Adults
This study will evaluate the safety, tolerability, and systemic exposure of an experimental influenza (flu) treatment medication called DAS181.
- Trial name
- NCT00527865
- Testing
- DAS181
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Ansun Biopharma, Inc.
Influenza, Seasonal Influenza
Yearly Strain Variation Study, 2009/2010
The purpose of this study is to verify the immunogenicity and tolerance of a trivalent seasonal influenza vaccine with strain composition according to World Heath Organization/European Union (WHO/EU) recommendation for the…
- Trial name
- NCT00943657
- Testing
- Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]
- Where
- Austria
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza Immunization, Healthy Volunteers
Post-marketing Surveillance Study for the Safety of Efluelda® Pre-filled Syringe
To objective of this study is to investigate the incidence of adverse events (AEs) and adverse drug reactions (ADRs) occurred following administration of Efluelda® in adults aged 65 years or older under routine clinical practice…
- Trial name
- NCT07282795
- Testing
- Efluelda® Pre-filled syringe
- Where
- 15 sites in South Korea
- Volunteers
- 670 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults
A single center, randomized clinical trial is to be conducted in healthy adults (18-60 years) to evaluate the safety and immunogenicity and study the cell-mediated Immunity of Sinovac's H1N1 influenza A Vaccine (PANFLU.1) with…
- Trial name
- NCT01008137
- Testing
- H1N1 influenza A Vaccine (PANFLU.1), Trivalent Inactivated Influenza Vaccine (ANFLU)
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Comparison of the Safety of Flublok® Versus Licensed IIV in Healthy, Medically Stable Adults ≥ 50 Years of Age
The hypothesis for this trial is that the incidence of a pre-defined composite of common systemic hypersensitivity adverse events for Flublok recipients is non-inferior to that reported for licensed IIV recipients.
- Trial name
- NCT01825200
- Testing
- Flublok, Afluria
- Where
- 14 sites in United States
- Volunteers
- 2,640 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza, Orthomyxoviruses
Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects
Primary Objective: To describe the immune response to a single administration of 2 formulations of the investigational cell-based influenza vaccines in healthy adult subjects.
- Conditions
- Influenza, Orthomyxoviruses, Myxovirus Infection
- Trial name
- NCT00845429
- Testing
- Influenza virus vaccine - cell based (2007-2008 Formulation), Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation)
- Where
- 15 sites in United States
- Volunteers
- 729 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza
Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)
This is a multi-center, randomized, two stage, double-blind, placebo-controlled administration study comprising 200 healthy participants.
- Trial name
- NCT01146119
- Testing
- Multimeric-001, 500 mcg, Adjuvanted PBS, PBS and TIV 15%
- Where
- 2 sites in Israel
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza, Healthy
Study to Evaluate the Safety of 3 New 6:2 Influenza Virus Reassortants in Adults
This prospective annual release study is designed to evaluate the safety on new influenza virus vaccine strains to be included in FluMist Quadrivalent for the 2013-2014 influenza season.
- Trial name
- NCT01859143
- Testing
- Trivalent Influenza Vaccine
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
The objective of this study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A in children aged between 3 and 17 years.
- Trial name
- NCT00972517
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 8 sites in Germany
- Volunteers
- 245 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity Study of Two Doses of an Inactivated H5N1 Influenza Vaccine (Whole Virion, Vero Cell Derived)
The objectives of this Phase I/II study are to assess the safety and immunogenicity of two different dose levels of a non-adjuvanted H5N1 influenza vaccine in a healthy young adult population.
- Trial name
- NCT00517517
- Testing
- Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation
- Where
- 4 sites in Hong Kong, Singapore
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza Immunization
Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years
The purpose of this study was to demonstrate the non-inferior HAI immune response of quadrivalent recombinant influenza vaccine (RIV4) vs licensed Egg-Based Quadrivalent Influenza Vaccine (IIV4) for the 4 strains based on the…
- Trial name
- NCT05513391
- Testing
- Recombinant influenza vaccine (RIV4), Quadrivalent influenza vaccine (IIV4)
- Where
- 31 sites in United States, Poland and 1 more
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Immunogenicity and Safety Evaluation of QIS in Healthy Subjects
The purpose of this study was to evaluate the antibody response to each of the four influenza vaccine strains included in the study vaccine, as measured by hemagglutination inhibition (HAI) at 4 weeks after the last dose of the…
- Trial name
- NCT04101435
- Testing
- AdimFlu-S (QIS)
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza
Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults
The purpose of this study were to obtain additional evidence in support of the safety and immunogenicity of a recombinant hemagglutinin (rHA) vaccine in an elderly population, and to establish non-inferiority of the…
- Trial name
- NCT00395174
- Testing
- Influenza Vaccination
- Where
- 7 sites in United States
- Volunteers
- 870 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Healthy Volunteers
Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.
Influenza (flu) viruses change continuously, therefore also the parts of viruses used in influenza vaccines can vary from year to year.
- Trial name
- NCT00346723
- Testing
- Influvac® subunit influenza vaccine for i.m./deep s.c.injection
- Where
- Belgium
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Solvay Pharmaceuticals
Influenza
Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults
The main purpose of this study is: to evaluate the efficacy and safety of MMH-407 in the treatment of influenza in outpatient adults.
- Trial name
- NCT04250311
- Testing
- MMH-407
- Where
- 20 sites in Russia
- Volunteers
- 314 people
- Sponsor
- Materia Medica Holding
Influenza
Study to Evaluate the Immune Response and the Safety of Fluarix TM/ Influsplit SSW® 2010/2011 or Pandemrix TM
The aim of this study is to evaluate the immune response and the safety of one injection of FluarixTM/ Influsplit SSW® 2010/2011 or Pandemrix TM in subjects who had received a single Pandemrix TM dose at least 6 months preceding…
- Trial name
- NCT01160237
- Testing
- PandemrixTM, FluarixTM/ Influsplit SSW® 2010/2011
- Where
- 5 sites in Germany
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine
The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.
- Trial name
- NCT00735475
- Testing
- CSL Limited Influenza Virus Vaccine (Afluria®), US Licensed Influenza Virus Vaccine (Fluzone®)
- Where
- 13 sites in United States
- Volunteers
- 1,268 people, healthy volunteers welcome
- Sponsor
- Seqirus
Pandemic, Avian Influenza
Immunogenicity, Safety and Tolerability of Prepandemic Influenza and Seasonal Influenza Vaccine in Adult Subjects
This study evaluates the immunogenicity, safety and tolerability of an H5N1 vaccine with a seasonal trivalent influenza vaccine, containing the strains recommended by WHO for the 2007 influenza season in the Southern Hemisphere.
- Trial name
- NCT00481065
- Testing
- MF59-eH5N1, eTIV_a, MF59-eH5N1 + eTIV_a
- Where
- Colombia
- Volunteers
- 405 people, healthy volunteers welcome
- Sponsor
- Novartis
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.